Veana Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: Portland OR United States (2012)

Organization Overview

First Clinical Trial
2019
NCT04120246
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Veana Therapeutics | Veana Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

alpha-tocopheryloxyacetic acid (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2